Article
Rational Design, Synthesis, Biological Evaluation, and In Silico Study of N-Cinnamamide/Benzamide-(4-(Substituted Phenyl)-6-(4-Cyclohexylphenyl)pyrimidin-2-Yl) Derivatives as EGFR Inhibitors Targeting EGFRWT, EGFRT790M, and EGFRL858R /T790M/C797S in NSCLC.
Chemical biology & drug design - 1 Sept 2026
Pal Rohit, Matada Gurubasavaraja Swamy Purawarga, Teli Ghanshyam, Bv Manjushree, Moulishankar Anguraj, Chawla Viney, Chawla Pooja A
Abstract excerpt
Non-small cell lung cancer (NSCLC), driven by mutations in the epidermal growth factor receptor (EGFR), presents significant therapeutic challenges, particularly due to drug resistance. This study describes the design, synthesis, and evaluation of a series of novel N-Cinnamamide/benzamide-(4-(substituted phenyl)-6-(4-cyclohexylphenyl)pyrimidin-2-yl) derivatives (Ri-Rxii) as EGFR inhibitors. Among these, compound...
Read the complete abstract on PubMedTopics
- Humans
- ErbB Receptors
- Carcinoma, Non-Small-Cell Lung
- Drug Design
- Protein Kinase Inhibitors
